newsfilter
← Latest News
GlobeNewswire·

Amryt to Report Q2 2022 Results on August 4, 2022

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financia